ArticleActa dermato-venereologica2025
LAight Therapy is an Effective and Gentle Treatment in Adolescents Suffering from Hidradenitis Suppurative: Results from 96 Patients Using Real-world Data.
Article in Acta dermato-venereologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hidradenitis suppurativa (HS) is a chronic skin condition characterized by the formation of painful nodules, abscesses, and tunnels, typically in intertriginous areas. While HS primarily affects adults, it causes in particular severe distress when it affects adolescent patients. Physicians prefer to avoid the use of systemic medications and surgery in children due to the potential side effects, psychological burden, and long-term consequences. The device-based LAight® therapy combines intense pulsed light and radiofrequency and received EU-wide approval in 2017 for the treatment of adults with all severities of HS. Since 2017, 96 adolescent patients in Germany and Austria have been treated off-label with LAight. A mixed model for repeated measures over 36 weeks on the endpoints Hidradenitis Suppurativa Severity Score System (IHS4), NRS Pain, and Dermatology Life Quality Index (DLQI) showed that patients starting treatment with a high burden significantly benefited from treatment, while those starting with a low burden could be effectively stabilized at a low level. HS and its management can cause considerable stress and anxiety for children and their families. Gentle and well-tolerated treatments, such as LAight therapy, can contribute to a more positive experience for patients and consequently improve their quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.